# Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status)

> **NCT06806228** · PHASE1 · SUSPENDED · sponsor: **Petrov, Andrey** · enrollment: 10 (estimated)

## Conditions studied

- Glioblastoma Multiforme
- Diffuse Midline Glioma, H3 K27M-Mutant
- Gliosarcoma
- Giant Cell Glioblastoma
- GBM

## Interventions

- **BIOLOGICAL:** S-Gboxin

## Key facts

- **NCT ID:** NCT06806228
- **Lead sponsor:** Petrov, Andrey
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2026-03-20
- **Primary completion:** 2027-10-10
- **Final completion:** 2027-12-10
- **Target enrollment:** 10 (ESTIMATED)
- **Why stopped:** The study protocol will be changed
- **Last updated:** 2025-11-19

## Collaborators

- Lytvin,Ruslan

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06806228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06806228, "Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06806228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*